Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 157-169

  Xu, Cong ^a,b   Langenheim, John F ^a,b   Chen, Wen Y ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

Breast cancer; Co culture; HER2 Neu; Prolactin; Prolactin receptor; Prolactin receptor antagonist

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; G 129R; HORMONE INHIBITOR; PROLACTIN; PROLACTIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL FIBROBLAST; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STROMA CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; COCULTURE TECHNIQUES; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROLACTIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84863920205     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1954-3     Document Type: Article

References (44)

1. EW LaPensee N Ben-Jonathan 2010 Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy Endocr Relat Cancer 17 2 R91 R107 20071456 10.1677/ERC-09-0253 1:CAS:528:DC%2BC3cXptV2mu7s%3D
2. MD Schroeder J Symowicz LA Schuler 2002 PRL modulates cell cycle regulators in mammary tumor epithelial cells Mol Endocrinol 16 1 45 57 11773438 10.1210/me.16.1.45 1:CAS:528:DC%2BD38XhvVCitw%3D%3D
3. K Liby, et al. 2003 Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth Breast Cancer Res Treat 79 2 241 252 12825859 10.1023/A:1023956223037 1:CAS:528:DC%2BD3sXktV2qu74%3D
4. J Tao, et al. 2011 PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin Mol Endocrinol 25 9 1565 1578 21719533 10.1210/me.2011-0062 1:CAS:528:DC%2BC3MXht1ykt73I
5. AS Goldhar, et al. 2005 Prolactin-induced expression of vascular endothelial growth factor via Egr-1 Mol Cell Endocrinol 232 1-2 9 19 15737464 10.1016/j.mce.2005.01.005 1:CAS:528:DC%2BD2MXhvVCrsro%3D
6. MV Maus SC Reilly CV Clevenger 1999 Prolactin as a chemoattractant for human breast carcinoma Endocrinology 140 11 5447 5450 10537179 10.1210/en.140.11.5447 1:CAS:528:DyaK1MXmvFemurk%3D
7. CV Clevenger, et al. 2003 The role of prolactin in mammary carcinoma Endocr Rev 24 1 1 27 12588805 10.1210/er.2001-0036 1:CAS:528: DC%2BD3sXhslOgsb8%3D
8. PA Furth, et al. 2011 Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer Breast Cancer Res 13 5 220 22018398 10.1186/bcr2921 1:CAS:528:DC%2BC38Xms1CnsQ%3D%3D
9. K Sakamoto, et al. 2010 Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer Oncogene 29 39 5359 5369 20639901 10.1038/onc.2010.274 1:CAS:528:DC%2BC3cXovFCntrk%3D
10. AS Sultan H Brim ZA Sherif 2008 Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition Cancer Sci 99 2 272 279 18271926 10.1111/j.1349-7006.2007.00685.x 1:CAS:528:DC%2BD1MXjs1ygtb4%3D
11. CV Clevenger T Torigoe JC Reed 1994 Prolactin induces rapid phosphorylation and activation of prolactin receptor-associated RAF-1 kinase in a T-cell line J Biol Chem 269 8 5559 5565 8119890 1:CAS:528:DyaK2cXhvVens7g%3D
12. R Das BK Vonderhaar 1996 Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells Oncogene 13 6 1139 1145 8808687 1:CAS:528:DyaK28XmtFeku7s%3D
13. E Aksamitiene, et al. 2011 Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells Cell Signal 23 11 1794 1805 21726627 10.1016/j.cellsig.2011.06.014 1:CAS:528:DC%2BC3MXhtVCntr7P
14. C Reynolds, et al. 1997 Expression of prolactin and its receptor in human breast carcinoma Endocrinology 138 12 5555 5560 9389544 10.1210/en.138.12.5555 1:CAS:528:DyaK2sXnsFOqs7k%3D
15. E Ginsburg, et al. 2010 Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies BMC Cancer 10 678 21144038 10.1186/1471-2407-10-678 1:CAS:528:DC%2BC3cXhs1Wiu7fE
16. ED Galsgaard, et al. 2009 Re-evaluation of the prolactin receptor expression in human breast cancer J Endocrinol 201 1 115 128 19153125 10.1677/JOE-08-0479 1:CAS:528:DC%2BD1MXlsVWktLs%3D
17. SS Tworoger SE Hankinson 2006 Prolactin and breast cancer risk Cancer Lett 243 2 160 169 16530327 10.1016/j.canlet.2006.01.032 1:CAS:528: DC%2BD28XhtVGitr7M
18. SS Tworoger P Sluss SE Hankinson 2006 Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women Cancer Res 66 4 2476 2482 16489055 10.1158/0008-5472.CAN-05- 3369 1:CAS:528:DC%2BD28XhsFaltro%3D
19. SS Tworoger, et al. 2011 The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study Breast Cancer Res 13 5 R99 22017816 10.1186/bcr3040 1:CAS:528: DC%2BC38Xms1Cnug%3D%3D
20. Emde A., Kostler WJ, and Yarden Y (2010) Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol [Epub ahead of print]
21. C Gutierrez R Schiff 2011 HER2: biology, detection, and clinical implications Arch Pathol Lab Med 135 1 55 62 21204711
22. J Frasor G Gibori 2003 Prolactin regulation of estrogen receptor expression Trends Endocrinol Metab 14 3 118 123 12670737 10.1016/S1043-2760(03) 00030-4 1:CAS:528:DC%2BD3sXisV2ns7Y%3D
23. D Sharma, et al. 2006 Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes Cancer Res 66 12 6370 6378 16778215 10.1158/0008-5472.CAN-06-0402 1:CAS:528:DC%2BD28XlvVSku78%3D
24. SJ Frank 2008 Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling J Mammary Gland Biol Neoplasia 13 1 119 129 18236142 10.1007/s10911-008-9065-9
25. KC Carver LA Schuler 2008 Prolactin does not require insulin-like growth factor intermediates but synergizes with insulin-like growth factor I in human breast cancer cells Mol Cancer Res 6 4 634 643 18403642 10.1158/1541-7786.MCR- 07-2069 1:CAS:528:DC%2BD1cXksFKmsL8%3D
26. ML Scotti, et al. 2008 Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells Breast Cancer Res Treat 111 2 241 250 17955362 10.1007/s10549-007- 9789-z 1:CAS:528:DC%2BD1cXptVCntLc%3D
27. NA Bhowmick EG Neilson HL Moses 2004 Stromal fibroblasts in cancer initiation and progression Nature 432 7015 332 337 15549095 10.1038/nature03096 1:CAS:528:DC%2BD2cXpvVCjtLw%3D
28. WS Dalton 1999 The tumor microenvironment as a determinant of drug response and resistance Drug Resist Updat 2 5 285 288 11504502 10.1054/drup.1999.0097 1:CAS:528:DC%2BD3cXhtFOksLo%3D
29. MJ Campbell, et al. 2002 Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse In Vitro Cell Dev Biol Anim 38 6 326 333 12513120 10.1290/1071-2690(2002)038<0326: EAFCLD>2.0.CO;2 1:CAS:528:DC%2BD3sXhtVSrsro%3D
30. Nagy A (2003) Manipulating the mouse embryo: a laboratory manual, vol.X, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 764
31. T Yamauchi, et al. 2000 Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer J Biol Chem 275 43 33937 33944 10938266 10.1074/jbc.M000743200 1:CAS:528: DC%2BD3cXnvVyjtLs%3D
32. DJ Slamon, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 707 712 2470152 10.1126/science. 2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D
33. CL Vogel, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528: DC%2BD38XhsVGmt7o%3D
34. LA Hazlehurst TH Landowski WS Dalton 2003 Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death Oncogene 22 47 7396 7402 14576847 10.1038/sj.onc.1206943 1:CAS:528:DC%2BD3sXotlajurY%3D
35. L Huck, et al. 2010 Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression Proc Natl Acad Sci U S A 107 35 15559 15564 20713705 10.1073/pnas.1003034107 1:CAS:528:DC%2BC3cXhtFaks7nN
36. P Cirri P Chiarugi 2011 Cancer associated fibroblasts: the dark side of the coin Am J Cancer Res 1 4 482 497 21984967 1:CAS:528:DC%2BC3MXms1Kntrc%3D
37. G Ayala, et al. 2003 Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer Clin Cancer Res 9 13 4792 4801 14581350 1:CAS:528:DC%2BD3sXosVGjsbg%3D
38. T Dittmar, et al. 2002 Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR FASEB J 16 13 1823 1825 12354693 1:CAS:528: DC%2BD38XoslOgt7w%3D
39. R Ben-Levy, et al. 1994 A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway EMBO J 13 14 3302 3311 7913890 1:CAS:528:DyaK2cXltlWhsL8%3D
40. N Akhtar CH Streuli 2006 Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia J Cell Biol 173 5 781 793 16754961 10.1083/jcb.200601059 1:CAS:528:DC%2BD28Xls1Shs70%3D
41. CH Streuli, et al. 1995 Stat5 as a target for regulation by extracellular matrix J Biol Chem 270 37 21639 21644 7665578 10.1074/jbc.270.37.21639 1:CAS:528:DyaK2MXotFaju7c%3D
42. GS Zoubiane, et al. 2004 A role for the cytoskeleton in prolactin-dependent mammary epithelial cell differentiation J Cell Sci 117 Pt 2 271 280 14676278 10.1242/jcs.00855 1:CAS:528:DC%2BD2cXhtVamsLY%3D
43. T Galbaugh YB Feeney CV Clevenger 2010 Prolactin receptor-integrin cross-talk mediated by SIRP alpha in breast cancer cells Mol Cancer Res 8 10 1413 1424 20826546 10.1158/1541-7786.MCR-10-0130 1:CAS:528:DC%2BC3cXht12ksLnF
44. W Guo, et al. 2006 Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis Cell 126 3 489 502 16901783 10.1016/j.cell.2006.05.047 1:CAS:528:DC%2BD28XosFGjtbs%3D